United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human Sperm-Antibody ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:Anti-Spermatozoa Antibody, Anti-Sperm Antibody
  • Species:Human
Cat. No. Size Price


RIS0017R 96 wells (1 kit) $508,75
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Description

The RIS0017R Human Sperm-Antibody ELISA is an enzyme immunoassay for the measurement of antibodies directed against human spermatozoa in serum. It is intended for research use only. The device is intended to be used as an aid for the diagnosis of immunologically caused disorders of fertility; The device is not intended to be used for the detection of poly- and monoclonal gammopathies.

Applications

Serum

Sample Requirements

50 µl (diluted)

Shipping

On blue ice packs. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

31–250 U/ml

Limit of Detection

3.367 U/ml

Intra-assay (Within-Run)

CV = 3.75%

Inter-assay (Run-to-Run)

CV = 11.1%

Spiking Recovery

98%

Dilution Linearity

102%

Summary

Features

  • RUO
  • calibration range 31-250 U/ml
  • limit of detection 3.367 U/ml
  • quality control

Research topic

Reproduction

Summary

Antibodies directed against spermatozoa antigens may cause infertility in women or men. The application of the Sperm Antibody ELISA is recommended for the diagnosis of immunologically caused disorders of fertility. Unwanted childlessness is a growing problem with which up to 20% of all couples in the reproductive age are confronted temporarily or long-term. In 5-20 % of these cases the presence of anti-spermatozoa antibodies in the male or the female patient is detectable [1,2,15]. The definition of infertility according to the WHO (WHO Laboratory Manual for the Examination of Human Semen and Semen CervicalMucus Interaction, 1999) is the absence of a conception within 12 months of unprotected intercourse. The main cause of an immunological fertility disorder is the formation of antibodies directed against spermatozoa antigens. Anti-spermatozoa antibodies (ASA) exert heterogeneous effects on the ability of spermatozoa to fertilize. The inhibiting effect of ASA on the motility of spermatozoa by binding to their surface and by agglutinating processes is well-known [3]. The penetration of the spermatozoa into the cervical mucus is impaired by the presence of ASA in the seminal plasma and/or in the cervical mucus [4]. ASA negatively influence the capacitation and the acrosome reaction of spermatozoa and thereby impede the interaction of the spermatozoa with the oocyte [5,6]. The interaction of the spermatozoon with the oocyte and the subsequent binding to and penetration of the zona pellucida may be inhibited by ASA. The following fusion of the oocyte and a spermatozoon may also be impaired by the presence of ASA [7,8]. The rate of pregnancies in couples with ASA on the part of the man or the woman was shown to be 38% lower compared to the control groups [9]. Furthermore an influence on the implantation and on the early embryological development could be confirmed. An association of ASA and miscarriages is discussed. The frequency of ASA in infertile couples amounts to 20% [10,11]. ASA may occur dissolved in the ejaculate or bound to the surface of spermatozoa. ASA may be found in men and in women [12]. In women, ASA may be found in cervical mucus, oviduct liquid and follicular liquid. Men having more than 50% of their spermatozoa coated with anti-spermatozoa antibodies show a conspicuously reduced rate of fertility [13]. ASA have been shown to be associated with chronic prostatitis which has a negative effect on male reproductive function [14].

Related Products Docs
Subscribe to Our Newsletter! Discover News from
BioVendor R&D
Subscribe Now
Subscribe to Our Newsletter! Discover News from
BioVendor R&D
Subscribe Now
zavřít